All In Biotech

Drug Trial Radar · NCT03977207

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Jul 20, 2020

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jun 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication in chronic kidney disease patients, and prior evidence shows that higher TSH levels, even within the normal laboratory range, are strongly associated with impaired quality of life and cardiovascular disease in this population. Levothyroxine is one of the most frequently prescribed medications in chronic kidney disease, yet its efficacy and safety in these patients have not been well-studied. Hence, this study will investigate 1) whether levothyroxine improves patient-centered (e.g., health-related quality of life, physical performance, strength) and 2) cardiovascular (e.g., coronary artery calcification, endothelial function, systolic function) outcomes in dialysis patients, and 3) if thyroid hormone replacement exerts classic metabolic effects (i.e., changes in body fat and resting energy expenditure) in this population.

Conditions

  • Thyroid; Functional Disturbance
  • Hypothyroidism
  • Hemodialysis

Interventions

  • Levothyroxine SodiumDrug

    Thyroid hormone supplement

  • PlacebosDrug

    Placebo oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 0 (pre-trial/baseline)
  2. Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 12
  3. Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component ScoreTime frame: Week 24
  4. Coronary Artery Calcification (CAC) - Volume ScoreTime frame: Week 0 (pre-trial/baseline)
  5. Coronary Artery Calcification (CAC) - Volume ScoreTime frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.